1. Dual Antiretroviral Therapy

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Current Paradigm: Triple Therapy Is Very Effective

5. Good Adherence With Single-Tablet Triple-Therapy Regimens

6. Recent Advances: Agents and Regimens

7. From Triple Therapy to Dual Therapy

8. From Triple Therapy to Dual Therapy Potential Advantages

9. From Triple Therapy to Dual Therapy Potential Advantages (cont)

10. Dual Therapy: Some Early Attempts That Fell Short Maintenance Treatment

11. Dual Therapy: Some Early Attempts That Fell Short Initial Treatment

12. Dual Therapy Success With PI/b + 3TC Regimens Initial Treatment

13. Dual Therapy Success With PI/b + 3TC Regimens Initial Treatment

14. From PI/b-Based to Integrase Inhibitor-Based Regimens

15. Integrase Inhibitor-Based 2-Drug Regimens DTG + 3TC in Treatment-Naive Patients

16. Integrase-Based 2-Drug Regimens DTG + 3TC in Treatment-Experienced Patients

17. Long-Acting Injectables: CAB/RPV Studies

18. DTG/RPV: First 2-Drug STR SWORD 1 and SWORD 2

19. SWORD: Tolerability and Safety

20. DTG/RPV: Indication

21. Patient Selection for DTG/RPV

22. Concluding Remarks